HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice.

AbstractBACKGROUND:
We have previously demonstrated that intranasal vaccination of highly susceptible BALB/c mice with whole Leishmania amazonensis antigens (LaAg) leads to protection against murine cutaneous leishmaniasis. Here, we evaluate the response of partially resistant C57BL/6 mice to vaccination as a more representative experimental model of human cutaneous leishmaniasis.
METHODS:
C57BL/6 mice from different animal facilities were infected with L. amazonensis (Josefa strain) to establish the profile of infection. Intranasal vaccination was performed before the infection challenge with two doses of 10 μg of LaAg alone or associated with the adjuvant ADDAVAX® by instillation in the nostrils. The lesion progression was measured with a dial caliper and the parasite load by limited dilution assay in the acute and chronic phases of infection. Cytokines were quantified by ELISA in the homogenates of infected footpads.
RESULTS:
C57BL/6 mice from different animal facilities presented the same L. amazonensis infection profile, displaying a progressive acute phase followed by a controlled chronic phase. Parasites cultured in M199 and Schneider's media were equally infective. Intranasal vaccination with LaAg led to milder acute and chronic phases of the disease. The mechanism of protection was associated with increased production of IFN-gamma in the infected tissue as measured in the acute phase. Association with the ADDAVAX® adjuvant did not improve the efficacy of intranasal LaAg vaccination. Rather, ADDAVAX® reduced vaccination efficacy.
CONCLUSION:
This study demonstrates that the efficacy of adjuvant-free intranasal vaccination with LaAg is extendable to the more resistant C57Bl/6 mouse model of infection with L. amazonensis, and is thus not exclusive to the susceptible BALB/c model. These results imply that mucosal immunomodulation by LaAg leads to peripheral protection irrespective of the genetic background of the host.
AuthorsJuliana Elena Silveira Pratti, Tadeu Diniz Ramos, Joyce Carvalho Pereira, Alessandra Marcia da Fonseca-Martins, Diogo Maciel-Oliveira, Gabriel Oliveira-Silva, Mirian França de Mello, Suzana Passos Chaves, Daniel Claudio Oliveira Gomes, Bruno Lourenço Diaz, Bartira Rossi-Bergmann, Herbert Leonel de Matos Guedes
JournalParasites & vectors (Parasit Vectors) Vol. 9 Issue 1 Pg. 534 (10 06 2016) ISSN: 1756-3305 [Electronic] England
PMID27716449 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adjuvants, Immunologic
  • Antigens, Protozoan
  • Cytokines
  • Protozoan Vaccines
  • Interferon-gamma
Topics
  • Adjuvants, Immunologic
  • Administration, Intranasal
  • Animals
  • Antigens, Protozoan (immunology)
  • Cytokines (biosynthesis, immunology)
  • Disease Models, Animal
  • Immunomodulation
  • Interferon-gamma (biosynthesis, immunology)
  • Leishmania mexicana (immunology, isolation & purification)
  • Leishmaniasis, Cutaneous (genetics, immunology, prevention & control)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Parasite Load
  • Protozoan Vaccines (administration & dosage, immunology)
  • Vaccination

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: